Hemolytic uremic syndrome in the setting of COVID-19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature

Hemolytic uremic syndrome in the setting of COVID-19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature

IntroductionAs the global pandemic continues, new complications of COVID-19 in pediatric population have turned up, one of them being hemolytic uremic syndrome (HUS), a complement-mediated thrombotic microangiopathy (CM-TMA) characterized by triad of thrombocytopenia, microangiopathic hemolytic anem...

Full description

Bibliographic Details
Main Authors: Matija Matošević, Ivanka Kos, Maša Davidović, Maja Ban, Hana Matković, Ivan Jakopčić, Ivana Vuković Brinar, Ágnes Szilágyi, Dorottya Csuka, György Sinkovits, Zoltán Prohászka, Kristina Vrljičak, Lovro Lamot
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Pediatrics
Subjects:
hemolytic uremic syndrome
HUS
thrombotic microangiopathy
TMA
COVID-19
complement blockade
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2023.1092860/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2023.1092860/full

Similar Items